Cabaletta Bio (NASDAQ: CABA) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Cabaletta released 2Q21 earnings that were essentially a non-event, as is often the case for a clinical-stage company. More important are updates on the progress of lead program DSG3-CAART, and we are encouraged by the DesCAARTes trial update that no dose limiting toxicities or clinically relevant adverse events have been observed to date, while we await key target engagement data that the company expects to provide 3 to 6 months after completion of dosing of each cohort. Management also expects to submit an IND for MuSK-CAART in myasthenia gravis, and hold a pre-IND meeting with FDA for their PLA2R-CAART program in membranous nephropathy in 2H21. We maintain our $22 PT, and reiterate our Buy rating.”
To request access to the full report, visit https://ibn.fm/YjeoO
About Cabaletta Bio Inc.
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA(TM)) platform, in combination with Cabaletta’s proprietary technology, utilizes Chimeric AutoAntibody Receptor (“CAAR”) T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The company’s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes(TM) Phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the DesCAARTes(TM) Phase 1 clinical trial, please see www.clinicaltrials.gov. The company’s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis. For more information, visit the company’s website at www.cabalettabio.com.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.